SCHEMBL6295069

SCHEMBL6295069

CN1CCc2ccc(NC(=O)c3ccc(Cl)c([N+](=O)[O-])c3)cc2C1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 10/20 0.58
▸ MEN1 O00255 9/20 0.58
▸ MAPT P10636 9/20 0.57
▸ ALDH1A1 P00352 4/20 0.57
▸ SMN1; SMN2 Q16637 3/20 0.57
▸ KDM4E B2RXH2 1/20 0.55
▸ MAPK1 P28482 3/20 0.54
▸ NPC1 O15118 1/20 0.54
▸ RAB9A P51151 1/20 0.54
▸ TMPRSS2 O15393 1/20 0.53
▸ HTT P42858 1/20 0.52
▸ ROCK2 O75116 1/20 0.52
▸ LMNA P02545 3/20 0.52
▸ NPSR1 Q6W5P4 2/20 0.52
▸ POLB P06746 1/20 0.52
▸ XBP1 P17861 1/20 0.52
▸ HPGD P15428 1/20 0.51
▸ GAA P10253 1/20 0.51
▸ CASP3 P42574 1/20 0.51
▸ SENP7 Q9BQF6 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6298411 0.86 TMPRSS2 (0.65) KMT2AMEN1MAPTKDM4ENPC1
SCHEMBL29669758 0.85 MAPT (0.64) KMT2AMEN1MAPTALDH1A1SMN1; SMN2
SCHEMBL28937076 0.85 MAPT (0.64) KMT2AMEN1MAPTALDH1A1SMN1; SMN2
SCHEMBL6293967 0.84 ABCG2 (0.58) KMT2AMEN1MAPTMAPK1NPC1
SCHEMBL6298333 0.81 ROCK2 (0.66) SMN1; SMN2NPC1RAB9ATMPRSS2ROCK2
SCHEMBL6294865 0.81 MEN1 (0.62) KMT2AMEN1MAPTALDH1A1NPC1
SCHEMBL6293954 0.79 ROCK2 (0.77) KMT2AMEN1MAPTSMN1; SMN2KDM4E
SCHEMBL6299597 0.79 ROCK2 (0.61) TMPRSS2ROCK2
SCHEMBL6298413 0.79 ROCK2 (0.56) NPC1RAB9ATMPRSS2ROCK2
SCHEMBL27942800 0.78 KMT2A (0.72) KMT2AMEN1MAPTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6841560-B2 Substituted isoquinoline derivatives and their use as anticonvulsants SMITHKLINE BEECHAM P.L.C. (GB) 2005-01-11 — — US claimed
US-20030144320-A1 For treatment and/or prevention of anxiety, mania, depression, panic disorders, nerve sustem disorders SMITHKLINE BEECHAM P.L.C. 2003-07-31 — — US claimed
US-6841560-B2 Substituted isoquinoline derivatives and their use as anticonvulsants SMITHKLINE BEECHAM P.L.C. (GB) 2005-01-11 — — US disclosed
US-20040209912-A1 Substituted isoquinoline derivatives and their use as anticonvulsants SMITHKLINE BEECHAM P.L.C. 2004-10-21 — — US disclosed
US-20030144320-A1 For treatment and/or prevention of anxiety, mania, depression, panic disorders, nerve sustem disorders SMITHKLINE BEECHAM P.L.C. 2003-07-31 — — US disclosed
US-20010016657-A1 Substituted isoquinoline derivatives and their use as anticonvulsants SMITHKLINE BEECHAM P.L.C. 2001-08-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040209912-A1 Substituted isoquinoline derivatives and their use as anticonvulsants INA, GRIN2C, GRIN2A KMT2A 445/4885MEN1 3408/4885MAPT 353/4885
US-20010016657-A1 Substituted isoquinoline derivatives and their use as anticonvulsants INA, GRIN2C, GRIN2A KMT2A 445/4885MEN1 3408/4885MAPT 353/4885
US-20030144320-A1 For treatment and/or prevention of anxiety, mania, depression, panic disorders, nerve sustem disorders PNMT, SLC6A2, GABBR1 KMT2A 1389/4885MEN1 269/4885MAPT 1087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback